Furthermore, several studies have identified aberrant hypermethylation in the MLH1 promoter in up to 15% of GBM specimens [25–27], suggesting that a substantial subset of patients might benefit from DAC preconditioning. The gene discussed is MLH1; the disease is glioblastoma.